Receipt of the nasal live-attenuated influenza vaccine did not increase risk for respiratory deterioration or all-cause hospitalization among children with cystic fibrosis, study data showed.

Researchers assessed vaccine tolerance among 168 children, aged 2 to 18 years, with cystic fibrosis who received LAIV between October 2012 and January 2013. Study participants were followed for 56 days after initial vaccination. Days 0 to 28 after LAIV were considered the at-risk period and days 29 to 56 were considered the non-at-risk period.

Approximately 38% used inhaled and/or nasal corticosteroids at baseline, 19% used inhaled antibiotics and 3% used azithromycin.